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COS-7 cells transfected with human immunodeficiency virus type 1 (HIV-1) proviral DNA produce virus in
which three tRNA species are most abundant in the viral tRNA population. These tRNAs have been identified
through RNA sequencing techniques as tRNA3LY the primer tRNA in HIV-1, and members of the tRNALYS
isoacceptor family. These RNAs represent 60% of the low-molecular-weight RNA isolated from virus particles,
while they represent only 6% of the low-molecular-weight RNA isolated from the COS cell cytoplasm. Thus,
tRNALYS is selectively incorporated into HIV-1 particles. We have measured the ratio of tRNALYS molecules to
copies of genomic RNA in viral RNA samples and have calculated that HIV-1 contains approximately eight
molecules of tRNA3YS per two copies of genomic RNA. We have also obtained evidence that the Pr1609'&P°
precursor is involved in primer tRNA3LYS incorporation into virus. First, selective tRNALYS incorporation and
wild-type amounts of tRNALYS were maintained in a protease-negative virus unable to process Pr55gag and
Pr1609'9-P° precursors, indicating that precursor processing was not required for primer tRNA incorporation.
Second, viral particles containing only unprocessed Pr559'9 protein did not selectively incorporate tRNALYS,
while virions containing both unprocessed Pr551ag and Pr1609g9°' proteins demonstrated select tRNALYS
packaging. Third, studies with a proviral mutant containing a deletion of most of the reverse transcriptase
sequences and approximately one-third of the integrase sequence in the Pr16W'9-P° precursor resulted in the
loss of selective tRNA incorporation and an eightfold decrease in the amount of tRNA3LYS per two copies of
genomic RNA. We have also confirmed herein finding of a previous study which indicated that the primer
binding site is not required for the selective incorporation of tRNALYS.
A limited number of tRNAs derived from the infected host
cell are packaged into retroviruses during virus assembly (9, 11,
24, 31, 33). One of these is termed the primer tRNA because
it is used to prime the reverse transcriptase (RT)-catalyzed
synthesis of retroviral minus-strand DNA. All members of the
avian sarcoma and leukosis virus group examined to date use
tRNATrP as primer for reverse transcription (10, 14, 26, 33, 39,
40), whereas murine leukemia virus (MuLV) employs tRNAPrO
(13, 24, 37), and mouse mammary tumor virus utilizes tRNALYS
(25, 38). The 3'-terminal 18 nucleotides of primer tRNA are
complementary to a region near the 5' end of the 35S RNA,
termed the primer binding site (PBS). The sequence of this site
in human immunodeficiency virus type 1 (HIV-1) suggests that
the primer tRNA in this virus is also tRNALYS, one of the three
major tRNALYS isoacceptors in mammalian cells (28, 29).
Retroviral tRNA is found either in a free state or associated
with the viral genome (8, 10, 11, 38, 39). When the viral 70S
RNA complex is used to direct DNA synthesis catalyzed by
RT, one of these bound tRNAs, more tightly associated than
the others, serves as a primer for DNA synthesis (11, 18, 24, 37,
39). In HIV-1, the tightly associated tRNA is tRNA LS (16).
During viral assembly, tRNA packaging is selective, and in
HIV-1 produced by transfecting COS cells with HIV-1 proviral
DNA, the tRNALYs isoacceptors, tRNA2 and tRNA3YS are
the major-abundance tRNAs packaged (16). These tRNAs are
selected from over 100 different tRNA isoacceptor species in
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the cytoplasm, and we are investigating the mechanism respon-
sible for this process. Previous work has indicated that the
reduction or absence of viral genomic RNA incorporation does
not affect primer tRNA incorporation into virions (20, 26).
Because retrovirus are assembled by using Pr55Ma& and
Pr1609a9-J° precursors which are not cleaved until after viral
budding (17, 41), it is likely that the selection of tRNALYS
occurs by the binding of tRNALYS to either of these proteins.
PrMSag contains the amino acid sequence for nucleocapsid
protein (NC), and Pr1609agsPo contains the amino acid se-
quences for NC and RT. Both NC and RT (in their fully
processed forms) have been shown to bind to tRNA3'YS in vitro
(1, 27, 32). The absence of RT has also been reported to affect
the incorporation of primer tRNA in both murine (21) and
avian (26) retroviruses.
In this study, we determined the number of tRNALYS mole-
cules incorporated into wild-type HIV-1 and examined the role
of the PBS, viral protease, Pr55rag, and Pr1609agsPo on the
select incorporation of tRNALYS into virus particles. To do so,
we analyzed the tRNA population in wild-type and mutant
HIV-1 particles produced by transfecting COS-7 cells with
wild-type and mutant HIV-1 proviral DNA. The data obtained
provide suFporting evidence for the involvement of uncleaved
Pr1609a9Po in tRNALYS packaging.
MATERUILS AND METHODS
Plasmid construction. Schematic representations of the
plasmids used for the transfections carried out in this study are
shown in Fig. 1.
SVC21 BH10 contains wild-type HIV-1 proviral DNA se-
2065
2066 MAK ET AL.
B, SVC21 BH10
PBS
C, SVC21 P (-)
PBS Asp25-Arg25
EE3 r- gag
vPu nefI
eV,,,G
D, SVC21 MSCI
PBS NBCI mSCI
--~~~~~~~~~~F- re
VPU
E, pSVGAG-RRE-R
Sac I
l1 gag LRojw.
F, pSVGAGPOL-RIE-R P (-)
Sac I Aap25-Gly25
1iqac II
Sal I
rwlvii,
I Vol I IUREJ
FIG. 1. Structures of wild-type and mutant HIV-1 plasmids. SVC21 BH10 (B) contains the wild-type HIV-1 proviral DNA sequence. SVC21
P( -) (C) contains a protease-deficient HIV-1 proviral DNA due to a point mutation at amino acid 25 in the protease region (12). SVC21 MSC1
(D) is an in-frame RT deletion mutant derived from SVC21 BH10 as described in Materials and Methods. The dashed line in the SVC21 MSC1
diagram indicates the deletion region. pSVGAG-RRE-R (E) and pSVGAGPOL-RRE-R P( -) (F), which serve as templates for the synthesis of
Pr55gag and unprocessed P16099ag-Po, respectively, were constructed as previously described (34, 35).
quence. SVC21 P(-) differs from SVC21 BH10 by a single
point mutation at position 25 of the protease region, convert-
ing Asp-25 to Arg-25. Transfection of SVC21 P(-) produces
noninfectious viral particles containing wild-type genomic
RNA and unprocessed precursor proteins Pr55rag and
Pr16G0agIPo (12). Both SVC21 BH10 and SVC21 P(-) were
gifts from E. Cohen, University of Montreal.
SVC21 MSC1 contains an in-frame deletion of RT and
approximately one-third of the integrase sequence and was
derived from SVC21 BH10. SVC21 BH10 was completely
digested with the restriction enzyme MSC1 (New England
Biolabs). The resulting 12-kb fragment, containing the plasmid
vector and deleted HIV-1 genome, was fractionated by agarose
electrophoresis and, after extraction from the gel, further
purified by using a mini-spin column and phenol-chloroform
extraction. The fragment was ligated with T4 DNA ligase
(Pharmacia). DNA sequencing was performed to confirm the
deletion.
pSVGAG-RRE-R and pSVGAGPOL-RRE-R P(-) were
previously described (34, 35). Viral production from these two
plasmids requires cotransfection with the Rev protein expres-
sion vector pCMV-rev. Cotransfection of pSVGAG-RRE-R
with pCMV-rev produces virus-like particles containing un-
processed Pr55gag precursor protein, while cotransfection of
pSVGAGPOL-RRE-R P(-) with pCMV-rev produces virus-
like particles containing unprocessed Pr55gag and Pr160`ag9Po.
All restriction and modification enzymes were used as
specified by the manufacturer.
Production of wild-type and mutant HIV-1. COS-7 cells
were transfected with wild-type and mutant proviral DNAs by
the calcium phosphate method as previously described (17).
Virus was isolated from the cell culture medium 63 h post-
transfection. The supernatant was first centrifuged in a Beck-
man GS-6R rotor at 3,000 rpm for 30 min, and the virus was
then pelleted from the resulting supernatant by centrifuging in
a Beckman Ti45 rotor at 35,000 rpm for 1 h. The viral pellet
was then purified by centrifugation at 26,500 rpm for 1 h
through 15% sucrose onto a 65% sucrose cushion, using a
Beckman SW41 rotor.
Isolation of viral RNA and human placental tRNALYS isoac-
ceptors. Total viral RNA was extracted from viral pellets by the
guanidinium isothiocyanate procedure (4).
The purification of tRNALYS and tRNALys from human
placenta was performed as previously described (16). The term
tRNALYs refers to a population of two tRNALYS species which
differ by one base pair in the anticodon stem (28). In this
report, spots 1 and 2 are collectively referred to as tRNALY,
since we have not sufficiently characterized these two species to
distinguish tRNALYS from tRNALYs (16).
RNA labeling. The fractionated RNA samples were labeled
by the 32pCp 3'-end-labeling technique (3). To make 32pCp, 5
mCi Of [_y_3 P]ATP (specific activity, 3,000 Ci/mmol; Dupont
Canada) was dried down in a microcentrifuge tube by using N2,
100 [LI of a reaction solution containing 50 mM Tris-HCl (pH
9.2), 5 mM MgCl2, 3 mM dithiothreitol, 5% bovine serum
albumin (BSA), 1 K1M 3'-CMP, and 10 U of T4 kinase was
added, the reaction mixture was incubated at 37°C for 3 h, and
the conversion of 3'-CMP to 32pCp was monitored by using
polyethyleneimine thin-layer chromatography in 0.8 M
NH2SO4, which separates 2pCp from [32P]ATP.
The RNA was labeled with 32pCp as previously described (3,
18). After labeling, free 32pCp was removed from the labeled
macromolecules either by using homemade Sephadex G-50
(Pharmacia) spin columns equilibrated with TE buffer (10 mM
Tris [pH 7.5], 1 mM EDTA) or during the electrophoresis run.
Before analysis by polyacrylamide gel electrophoresis (PAGE),
the samples were heated at 90°C for 2 min.
One-dimensional (1D) and 2D PAGE. Viral RNA was
electrophoresed at 4°C in a Hoefer SE620 gel electrophoresis
apparatus. Gel size was 14 by 32 cm. The first dimension was
run in a 10% polyacrylamide-7 M urea gel for approximately
16 h at 800 V, until the bromophenol blue dye was beginning
to elute from the bottom of the gel. After autoradiography, the
piece of gel containing RNA was cut out, embedded in a
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second gel (20% polyacrylamide-7 M urea), run for 30 h (25W
limiting), and then subjected to autoradiography. All electro-
phoretic runs were carried out in 0.5 x TBE (1 x TBE is 5 mM
Tris, 5 mM boric acid, and 1 mM Na2EDTA). The electro-
phoretic gel patterns shown in this report show only low-
molecular-weight RNA, since the high-molecular-weight viral
genomic RNA cannot enter the polyacrylamide gels. Further-
more, these patterns represent only the most abundant tRNA
species present, since the high specific activities of the labeled
tRNAs used will reveal more minor-abundance species with
longer film exposures.
The signal intensity of each radioactive low-molecular-
weight RNA species in the 2D PAGE RNA pattern was
determined with a Phosphorlmager (Bio-Rad, Toronto, On-
tario, Canada).
Measurement of tRNA3YS by RNA-DNA hybridization. To
measure the amount of tRNA3Ys in viral RNA, we synthesized
an 18-mer DNA oligonucleotide complementary to the 3' 18
nucleotides of tRNA3LS (5'-TGGCGCCCGAACAGGGAC-
3'). This probe hybridizes specifically with tRNA3YS (16, 17)
and was hybridized to dot blots on Hybond N (Amersham) of
either purified human placental tRNALYS or total RNA from
wild-type and mutant viruses. The DNA oligomer was first 5'
end labeled with T4 polynucleotide kinase and [y-32P]ATP
(3,000 Ci/mmol; Dupont), and specific activities of 108 to 109
cpm/p,g were generally reached. Approximately 107 cpm of
oligomer was generally used per blot in hybridization reactions.
Measurement of viral genomic RNA by quantitative PCR.
(i) Labeling of primer. One nanomole of sense primer was
mixed with 50 ,uCi of [y-32P]ATP (Dupont) and end labeled
with 3 ,lI of T4 polynucleotide kinase (10 U/pJ; Pharmacia) in
kinase buffer (70 mM Tris-HCl [pH 7.5], 100 mM MgCl2, 50
mM dithiothreitol) at 37°C for 1 h. Free radioactive label was
removed by passage through a G-25 spin column.
(ii) Reverse transcription. Ten picomoles of cold antisense
primer was mixed with a known volume of viral RNA or in
vitro-transcribed RNA in a total volume of 16.5 pul. Three
drops of oil layer was placed on top of the primer-template mix
to avoid evaporation. Tubes containing primer-template mix
were heated at 85°C for 3 min and slowly cooled to room
temperature to allow primer-template annealing. Then 8.5 PA
of RT master mix (30 mM Tris-HCl [pH 8.3], 5 mM MgCl2, 6
mM dithiothreitol, 1.5 p,M deoxynucleoside triphosphates
(dNTPs), 0.5 ,ug of BSA, 10 U of RNase inhibitor [Promega],
5 U of Moloney MuLV RT [Pharmacia]) was added to the
primer-template mix. Reaction tubes were incubated at 37°C
for 1 h. RT activity was terminated by incubation at 95°C for 5
min.
(iii) PCR. Seventy-five microliters of PCR master mix (10 ,ul
of 10 x Taq DNA polymerase buffer [GIBCO/BRL], 10 pl of
2 mM dNTPs, 1 plA of 32P-labeled primer mix, 1.25 U of Taq
DNA polymerase [GIBCO/BRL]) was added to the reaction
tubes containing reverse transcription products, which were
incubated at 95°C and subjected to 19 cycles of amplification
(denaturation, 94°C, 1 min; annealing, 60°C, 1 min; elongation,
72°C, 3 min). Aliquots of PCR products were run on an 8%
polyacrylamide-7 M urea gel to separate amplification prod-
ucts from excess radioactive primers. The gel was dried at 80°C
for 2 h and then exposed to a phosphor-imaging screen for
quantitative measurement on a Phosphorlmager.
(iv) Quantitative determination of genomic RNA in wild-
type and mutant viral RNA samples. Sense primer JS1 (5'-
ATTCGGTTFAAGGCCAGGGGG-3') and antisense primer
JAl (5'-GGGATGGTTGTAGCTGTCCC-3') were used for
PCR amplification. A 148-bp fragment, corresponding to
HIV-1 IIIB DNA positions 843 to 990, was amplified.
A standard curve was established by using known amounts of
in vitro-transcribed RNA for reverse transcription-PCR (RT-
PCR). A 957-base RNA fragment (sense) was made from a
linearized DNA plasmid, pEA2, with T7 RNA polymerase
(pEA2 was kind gift from E. J. Arts, McGill AIDS Centre).
This RNA fragment corresponds to HIV-1 IIIB DNA positions
473 to 1420.
Genomic RNA in wild-type and mutant viral RNA samples
and in vitro transcript RNA were quantitated with a Phosphor-
Imager (Bio-Rad). The relative intensities of amplified signals
were used to determine the concentration of genomic RNA in
the viral samples, using the standard curve.
RESULTS
We have previously shown that the tRNALYS isoacceptors,
tRNALys and tRNALYS, are the major-abundance tRNAs that
are incorporated into infectious virus particles produced from
COS-7 cells transfected with HIV-1 proviral DNA (16). To
identify the specific viral proteins involved in the selective
packaging of these tRNA molecules, we transfected COS-7
cells with a series of wild-type and mutant HIV-1 expression
plasmids. The construction and characteristics of each expres-
sion plasmid are described in Materials and Methods, and the
relevant portion of each plasmid is shown in Fig. 1. The
plasmids include three HIV-1 proviral clones which express (i)
wild-type Pr55gag and PrlflgarPo, which are processed later
(pSVC21 BH10), (ii) unprocessed Pr55&ag and Prl609ar9Po
[pSVC21 P( - )], or (iii) wild-type processed Pr55fla products
and a severely deleted Pr1609a9P° which lacks 95% of the RT
domain and approximately one-third of the integrase sequence
(pSVC21 MSC1). These proviral clones also express all of the
viral proteins downstream of the Pr1609'9-P° coding region. In
addition, two simian virus 40 late expression plasmids that
express either unprocessed Pr55gag alone (pSVGAG-RRE-R)
or both unprocessed Pr55ar and Pr1609agP9P [pSVGAGPOL-
RRE-R P(-)] were used.
To analyze the low-molecular-weight RNAs present in viral
particles, total RNA was extracted, end labeled, and subjected
to 2D PAGE as described in Materials and Methods. Figure 2
shows the 2D PAGE patterns of tRNAs extracted from normal
COS-7 cells as well as from virus particles produced from the
cells transfected with the different vectors. Figure 2-A shows the
tRNA extracted from uninfected COS-7 cells. Previous studies
have identified spots 1 and 2 as tRNAlLY and spot 3 as tRNALYS
(16). To quantitate the amount of tRNA present in each spot,
the gel was subjected to phosphor-imaging analysis. Table 1
shows the quantitation of the tRNALYs spots from the various
gels. In untransfected COS-7 cells (Fig. 2A), approximately 6%
of the cellular tRNA was represented by tRNALYS, and the
tRNALYS ratio was close to 1 (Table 1). In contrast, in wild-type
virus (Fig. 2B), approximately 60% of the low-molecular-
weight RNA was tRNALYS. Thus, there was a 10-fold increase
in the relative concentration of tRNALYS in the virus compared
with the cytoplasm of COS cells; i.e., tRNALYS was selectively
incorporated into the virus. The tRNAlLY2s/tRNA3LYs ratio re-
mained similar to that found in the cytoplasm of COS cells,
indicating that the two major tRNALYs isoacceptor families are
packaged with equal efficiency.
Because HIV is assembled from the precursor polypeptides
Pr55gag and Prl609ar9Po, which are cleaved into multiple pro-
teins during or after viral budding, it was of interest to
determine whether the precursor molecules themselves could
mediate the selective incorporation of tRNALYS or whether
proteolytic cleavage was necessary to facilitate the specific
incorporation. Thus, the tRNA pattern was examined in
VOL. 68, 1994
2068 MAK ET AL.
L209S
lo«
00- 100*
j,4E SiStU%
:',;- f.S f:
4 * ;^ 2
..0i3'5'0>, 0': t:
'v 'f'S '< 4000Eto 000 0 0 SS00 A; S
i: 0,
'X''' i'iE: 'ff
.,,"'0 ,j'.00
s., $, 000
*?
:: ;: :::0:
S: lV 00 00
X,00 4.f'
:0, t.0X4'S:00 0'
fE t.t ;0;;:00 000 ;070:00
tS fi 0;
FIG. 2. 2D PAGE patterns of low-molecular-weight viral RNA. Electrophoretic conditions were as described in the text. (A) Uninfected COS
cell; (B) wild-type virus (SVC21 BH10); (C to F) mutant viruses SVC21 P(-) (C), SVC21 MSC1 (D), pSVGAG-RRE-R (E), and
pSVGAGPOL-RRE-R P(-) (F).
TABLE 1. Percentage of tRNALYS isoacceptors in
total cellular and viral tRNAa
tRNA % tRNALy/
source tRNA' tRNA_ 5RNAXY tRNALyS %tRNA3YS(spot 1) (spot 2) (spot 3)
COS cells 2.1 1.0 2.6 5.7 1.2
Constructsb
B 24.7 5.3 31.2 61.2 1.0
C 19.6 5.6 25.7 50.9 1.0
D 1.9 0.4 1.9 4.2 1.2
E 2.0 0.6 2.1 4.7 1.2
F 20.5 5.2 24.4 50.1 1.1
" Determined through phosphor-imaging analysis of the 2D PAGE patterns in
Fig. 2. Spots refcr to those in Fig. 2.
bSee Fig. 1.
particles produced from a proviral clone lacking an active viral
protease [pSVC21 P(-)]. This clone contains an inactive
protease due to a Asp-25-to-Arg-25 change in the active site,
and the particles produced from transfected cells remain in the
immature form containing only unprocessed Pr55gag and
Pr16WQag-Po (12). As shown in Fig. 2C and Table 1, approxi-
mately 50% of the low-molecular-weight RNA is tRNALYS,
with a tRNAL,S/tRNALYs ratio equal to 1.0.
Pr16W'g-P" is the most likely precursor protein to be in-
volved in tRNALYS packaging because it contains the sequences
for RT, a protein whose mature form has been shown to
interact with tRNALYs in vitro (1, 32). To investigate the role of
Pr1609-P" in select tRNALYs packaging, we transfected COS
cells with a proviral DNA (pSVC21 MSC1) which is missing
95% of RT sequences and approximately one-third of the
integrase sequence (Fig. 1C). In this mutant, Pr559'" is pro-
cessed. Figure 2D shows the low-molecular-weight RNA pat-
tern in the virus particles produced, and the Phosphor-imaging
analysis of the gel is presented in Table 1. The results indicate
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that while the tRNALYs isoacceptors are present in the virus,
they are not selectively packaged. The relative concentration of
the tRNALY, in the virus is similar to that found in the
cytoplasm of nontransfected cells, i.e., 4.2%. The deletion used
in this experiment was too large to allow mapping of the
precise region inPr-60¢g~-°" involved in selecting tRNALYS for
incorporation into the virus, but these data clearly demonstrate
the importance ofPrl60¢QagPo in the selection process.
On the other hand, viral particles containing only unproc-
essed Pi-55(l"M' (not Pri 60gag-P"I) do not selectively package
tRNALY, into virus. These particles were produced by trans-
fecting COS-7 cells with DNA construct E(pSVGAG-RRE-R;
Fig. 1) (34, 35). The low-molecular-weight RNA pattern of
these virus particles is shown in Fig. 2E, and phosphor-imaging
analysis of this pattern (Table 1) indicates that no select
tRNALYS incorporation occurs; i.e., 4.7% of the low-molecular-
weight viral RNA is tRNALYS. We also produced virus particles
by transfecting COS-7 cells with DNA construct F [pSVGAG-
POL-RRE-R P(-)]. These particles contain both unprocessed
P-55-"tg and Pr16W'91""'' (34, 35). The low-molecular-weight
RNA pattern of these virus particles is shown in Fig. 2F, and
phosphor-imaging analysis of this pattern (Table 1) indicates
that select tRNALYS incorporation occurs; i.e., 50% of the
low-molecular-weight viral RNA is tRNAL-Ys. This finding
further supports the importance of PrI60q6aig-p'" in tRNALys
selection. It should also be noted that construct F produces
viral genomic RNA lacking the PBS (as does construct E);
therefore, these experiments validate earlier results which
indicated that select tRNALYS incorporation into HIV-1 does
not require the presence of a PBS on the genomic RNA (16).
The results in Fig. 2 and Table I showed the effects of
mutations in the viral proteins on the ability to selectively
incorporate tRNAL-YS into virions, but these experiments did
not address the effects of these mutations on the absolute
amounts of tRNALYS incorporated into the virus particles. To
investigate this, we measured the tRNA LYs/genomic RNA ratio
in each of the RNA samples isolated from the wild-type and
mutant viruses (Fig. 3 and 4; Table 2).
We have previously demonstrated the ability of a DNA
probe complementary to the terminal 3' 18 nucleotides of
tRNA LYS to hybridize specifically with this tRNA (16). Total
viral RNAs from wild-type and mutant viruses were blotted
onto Hybond filter paper, and the amount of tRNAXLYS present
in each sample was determined through hybridization both to
these samples and to known amounts of purified human
placental tRNA"ys (Fig. 3). The amount of genomic RNA in
each sample was determined by quantitative PCR (Fig. 4). The
results were quantitated by phosphor-imaging analysis (Table
2).
We found that wild-type virus contain eight molecules of
tRNAkYs per two copies of genomic RNA (Table 2, RNA
source B). Similar amounts of tRNALYs were found in the
protease-negative mutant virus particles (RNA source C). The
virions lacking the RT and part of the integrase showed an
eightfold reduction in the amount of tRNA3Ys per two copies
of genomic RNA (RNA source D). On the other hand, the
amount of tRNALys per two copies of genomic RNA ratio was
unexpectedly high in virus particles produced from the expres-
sion vector producing only PrS559'i (RNA source E), since
these particles showed no specificity of tRNALYS incorporation.
The amount of tRNA Lys per two copies of genomic RNA was
also unexpectedly high in virus particles produced from the
expression vector producing both Pr55g'9 and PrI60g'-"'9
(RNA source F). These particles showed specific tRNALYs
incorporation, but the amount of tRNA LYs per two copies of
genomic RNA was approximately 14 times higher than that
A (ng) 0.1 0.2 0.6 1.0 5.0
tRNALys3 A @0
Viral RNA 0 0
samples B C D E F
B 125
o 100
0
a 75
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* 50
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FIG. 3. (A) Quantitation of tRNA3ys in viral RNA. The specificity
of the tRNAI ys DNA oligomer probe used has been described
previously (15). Purified human placenta tRNAL-Y' was used as an
external standard. Aliquots from the same viral RNA samples used to
quantitate genomic RNA in Fig. 4 were used to determine the amount
of tRNALys present. Volumes of viral RNA samples used for hybrid-
ization in lanes B to F were 2, 2, 1, 2, and 2 pl, respectively. (B)
tRNAL-vs standard curve. Hybridization signals of purified human
tRNALys were used to construct a standard curve. Concentrations of
tRNALys in viral RNA samples were calculated from this curve.
found in wild-type HIV-1. These high ratios could be explained
if there was a defect in constructs E and F which resulted in
virus particles that had a 10-fold decrease in their ability to
package genomic RNA. Recent data suggest that these con-
structs do produce viral particles defective in the packaging of
genomic RNA (3a).
DISCUSSION
As reported above, approximately 60% of viral low-molec-
ular-weight RNA in HIV-1 is tRNALYS, with 30% represented
by the primer tRNA, tRNALys. These results are similar to
those found for the primer tRNA, tRNATrP, in avian myelo-
blastosis virus (AMV) by using a very different technique,
aminoacylation (39). Primer tRNATrP represents 32% of free
viral tRNA in AMV. We have also determined the amount of
tRNA'-Ys and genomic RNA present in HIV-1 total viral RNA
and used this information to calculate the number of tRNALys
molecules per virion, assuming two copies of genomic RNA
per virion. By these calculations, wild-type HIV-1 contains
approximately eight molecules of tRNA'-Ys per virion. This
number is similar to the value of six to eight molecules of
primer tRNA per virion reported for Rous sarcoma virus (33)
and AMV (39).
In this report, we provide evidence supporting the hypoth-
esis that the unprocessed P060v-P"' is involved in selecting
tRNALYS for incorporation into HIV-1. First, studies with a
protease mutant clearly demonstrate that proteolysis of viral
protein precursors is not required for tRNALys incorporation.
A similar conclusion was reached from studies using the
MuLV (6) and avian leukemia virus (36) systems.
Second, viral particles containing only unprocessed Pr55-1t9
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FIG. 4. (A) Quantitative RT-PCR. RT-PCR was performed on in vitro-transcribed genomic RNA (used as an external standard) or on known
volumes of RNA samples isolated from virus produced by transfecting COS cells with constructs B to F (see Fig. 1), using viral RNA samples of
0.1, 0.1, 0.1, 1, and 1 ,ul, respectively. Amplified products were run on an 8% polyacrylamide-7 M urea gel to separate amplified products from
excess radioactive primers. Equal amounts of viral RNA samples were also used for PCR amplification without reverse transcription as a negative
control. (B) Genomic RNA RT-PCR standard curve. The relative intensities of amplified signals from in vitro-transcribed RNA were used to plot
a standard curve. Concentrations of genomic RNA from the viral RNA samples were calculated from this curve.
do not selectively incorporate tRNALYS, while virions contain-
ing unprocessed Pr55rag and Pr16V9-P° do. Thus, although
mature NC has been shown to bind to tRNALYS in vitro (1, 27),
the NC sequence in Pr55gag does not appear, by itself, to play
a major role in tRNALYS selection. We cannot yet rule out the
possibility that Pr55gag interacts cooperatively with Pr1609ag9P`
to select tRNALYS for incorporation. On the other hand, in
construct F, the absence of the genes for viral proteins
downstream of the vif gene shows that the protein products of
these genes are not required for select tRNALYS incorporation
(Rev protein is made on a separate plasmid in our transfection
system, and its participation in select tRNALYS incorporation,
while unlikely, cannot be ruled out). The ability of the virus
containing unprocessed Pr55gag and Pl6099ag-Po to selectively
incorporate tRNALYS in the absence of a PBS on the genomic
RNA is also consistent with results from other retrovirus
systems which indicate a lack of involvement of genomic RNA
in this process (20, 26).
Finally, removal of RT and integrase sequences from
Prl60gagPo' prevents selective tRNALYS incorporated per two
copies of genomic RNA. The effect of the alteration of
Pr1609ag9Po on tRNALYS incorporation indicates the impor-
tance of PrI609ag9P` in this process. The deletion in Pr1609ag9Pd
is large and could result in (i) an alteration in the conformation
of the molecule, (ii) more rapid degradation of the molecule,
or (iii) inability of the damaged Prl60PagPoI molecule to enter
the virus. However, our results are consistent with the evidence
TABLE 2. Molecules of tRNA3YS per two molecules
of genomic RNA
No. of No. of
molecules of ng of molecules of
sourcea genomic tRNA3YS/pl molecules of tRNA3Y/2sore RNA/Ipl of ofsample' tN3s/I molecules of
sampleb of sampled genomic RNA
B 2.0 x 109 0.34 8.0 x 109 8
C 2.3 x 109 0.34 8.0 x 109 8
D 3.0 x 109 0.06 1.4 x 109 1
E 1.7 x 108 0.03 8.5 x 108 10
F 2.0 x 108 0.46 1.1 x 1010 109
a See Fig. 1.
b Determined from Fig. 3.
c Determined from Fig. 4.
d A tRNA molecular size of 25,000 g/mol was used to calculate the number of
tRNA molecules.
that RT sequences are involved in tRNALYS selection. It is
known that mature RT (p66/pSi) interacts with primer tRNA
during reverse transcription (1, 32), and it has been shown in
both the avian sarcoma virus (26) and MuLV (21) systems that
a mutant virus lacking RT fails to selectively incorporate the
correct tRNA. Finer mutational analysis will be required to
determine whether RT sequences within the Pl601ag°I9l pro-
tein are involved in tRNALYS selection.
Wild-type HIV-1 contains approximately eight molecules of
tRNALYS per virion. Viruses unable to process precursor
proteins still incorporate eight molecules of tRNALYS per
virion, while those lacking RT and integrase reduce the
incorporation of tRNALYS approximately eightfold. Our calcu-
lations assume that these mutants incorporate normal amounts
of viral genomic RNA. This assumption is supported by the
findings that normal amounts of viral genomic RNA are
incorporated in a protease-negative avian leukemia virus mu-
tant (36) and in RT-negative avian and murine retroviruses
(21, 26).
Our results are also consistent with our unpublished data
(3a) showing that RNA from constructs resembling E and F
cannot be packaged into particles. This explains the unexpect-
edly high ratio of tRNA3YS molecules per two copies of
genomic RNA observed in these cases. Particles produced
from the plasmid expressing only unprocessed PrS55ag did not
show select tRNALYS incorporation yet contained 11 molecules
of tRNA3YS per two copies of genomic RNA. Particles pro-
duced from the plasmid expressing both unprocessed Pr55rag
and Pr1609ag9PI showed selective packaging of tRNALYS but
contained 109 molecules of tRNA3LY per two copies of
genomic RNA, a ratio 14-fold higher than found in wild-type
HIV-1. The 10-fold differences in the ratio of tRNA3YS per two
copies of genomic RNA seen between these two viral popula-
tions probably reflects a 10-fold difference in tRNALYS selective
packaging because of the presence of Pr1609rarP in one and
not the other. While it is not clear why the genomic RNA from
these constructs fail to be packaged, these results are consis-
tent with recent findings which indicate that the two regions
missing in our constructs, the 5' part of the genome through
the PBS and the region 3' of the vifgene (34, 35), are required
for genomic RNA packaging (30, 37a).
The tRNALys/tRNALYs ratios are similar in the cell's cyto-
plasm and in the virus. This finding indicates that these
tRNALYS isoacceptors are packaged with equal efficiency and
suggests that some common feature of these molecules is
J. VIROL.
SELECT tRNAL INCORPORATION INTO HIV-1 2071
recognized by a viral protein during packaging. Mature RT has
been shown to interact in vitro with the anticodon arm of
tRNALYS (1, 2, 32, 42), yet this region is quite different between
tRNA-YS and tRNA-Y,', differing by 6 of 17 bases. If this region
of the molecule serves as a recognition signal for packaging,
then the two different sequences in this arm must fold in
similar conformations. On the other hand, it is possible that the
interaction of Pr16Q¢'' with tRNA'-Ys in vivo is quite differ-
ent from the interaction studied in vitro with mature, pro-
cessed RT. This difference could be due to artifacts created in
the in vitro systems in which the interaction between mature
RT and tRNA`Ys are studied, but it is possible that the
interactions involved in packaging tRNALys are quite different
from the interaction between RT and tRNA Ys during reverse
transcription. For example, it has been postulated that the
tRNA binding site on RT may involve both p66 and p51
polypeptides in the RT dimer (19), but it is not known whether
Pr-60"1-"'9 can also form a dimer and, if so, interact with
tRNALYS in the dimer form. Besides the fact that tRNALys is
interacting with two different molecules during packaging and
reverse transcription, the tRNAX-ys may be in different states in
the cytoplasm and in the virus. For example, most cytoplasmic
tRNALYs is expected to be complexed with proteins such as
lysine tRNALys synthetase or the eukaryotic elongation factor
EF-lot, which carries tRNA to the ribosome (15, 23). It may
therefore be that the PrI606"¢" binding site on tRNA3YS is
composed of protein as well as RNA.
In a retrovirus, primer tRNA is present in a higher abun-
dance than most other tRNAs. Is this higher abundance a
requirement for its efficient function as a primer tRNA, or is
efficiency of function as a primer more influenced by specific
structural properties of the tRNA? Colicelli and Goff (5)
isolated a mutant MuLV which contained a PBS complemen-
tary to tRNAG"' rather than tRNAPrO, the normal primer
tRNA in this virus. These virus particles were infectious and
presumably could use tRNAG'" as the primer tRNA. Similar
results were also obtained in which a recombinant MuLV-
based retroviral vector containing a PBS for tRNAGIn or
tRNALYS instead of tRNAPr"' also appeared to be replicated,
using tRNAGIn or tRNA Ys as the primer for reverse transcrip-
tion (22). The concentration of tRNALYS relative to other viral
tRNAs is high in many retroviral systems examined, including
MuLV (40), but the relative concentration of tRNAGln in
MuLV has not been reported, and it would be of interest to
know whether the select incorporation of tRNAG'" into the
mutant virus or in the retroviral vector particles is required for
it to act efficiently as a primer for reverse transcription. As
mentioned above, evidence is presented here and elsewhere
that viral genomic RNA does not appear to be involved in the
selective incorporation of primer tRNA, including in the
MuLV system (20).
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